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The aim of the project was to detect the polymorphisms in the apo A1 gene, which 
might possibly be associated with the risk of atherosclerosis in claudicants. This aim 
was achieved by amplification of the three exons and four introns of the apo A1 gene 
and followed by sequencing of the amplicons. The annealing temperature estimated 
by gradient PCRS for the coding and non-coding regions was 60.5°C, 61.2°C, 
62.5°C, 59.7°C, 58.1°C and 57.8°C for 5’flanking, exon2/intronB/exon3, exon 3, 
intron C, exon 4 and 3’flanking, respectively. Altogether, 138 PCRs were undertaken. 
It was not possible to detect any high confidence polymorphism in the present sample 
size which was further reduced due to failed sequencing reactions in some samples. 
0nly 16 out of 60 samples were successful for sequencing reaction. None of them 
could be successfully sequenced with their both forward and reverse primers. Any 
true estimates of the allele and genotype frequencies of the mutations cannot be 
made from the observed small sample size. Also, depending on the sample size and 
the sequencing results, any inference as to how these mutations could be associated 
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1.1 Introduction  
Oxidative stress can be described as the presence of excess of free radicals and 
the ability of body to neutralize them. ROS/RNS (reactive oxygen species/reactive 
nitrogen species) are present in living cells and tissues in very low concentration 
under normal physiological conditions (figure 1.1). The balance between their 
rates of production and their rates of clearance by various antioxidant compounds 
and enzymes decides their concentrations. Their balance is changed by redox 
regulation, either by an increase in RNS/ROS production or decrease in the 
activity of the antioxidant system (Turko, I. & Murad, F, 2002).   
                  
 ROS/RNS  can either be free radicals, reactive anions containing oxygen or 
molecules containing oxygen which have the ability to produce free radicals eg, 
hydroxyl radical(OH˙), peroxynitrite (ONOO–) and hydrogen peroxide (H2O2). 
Superoxide (O2–˙) and other ROS are produced by oxidases and peroxidases in 
the body to perform useful functions. However, in disease states production 
increases over and above the requirements for normal metabolism which leads to 
the generation of potentially cytotoxic species. Superoxide is not itself very 
reactive but acts as a precursor for a number of ROS. These species modify the 
activity of antioxidant enzymes either by inactivation or leakage from cells, or by 
the release of metal ions from metalloproteins. The reactivity of ROS is increased 
when reduced with transition metal ions such as (Fe+2 or Cu+2) giving rise to 
hydroxyl radicals, or their interaction with a few haem proteins, or their reaction 
with myeloperoxidase which in turn forms hypochlorite, an oxidant which can 
damage proteins by producing chloramines which are long lasting (Rice-Evans, C 
& Bruckdorfer, K.R, 1995).  
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The major source of ROS amplification is the reaction of superoxide with nitric 
oxide (NO) producing a very potent oxidant, peroxynitrite. Its role has been 
discussed in detail in protein nitration below:  
 
Figure 1.1 Oxidative Stress (Fiers, W. et al, 1999.). 
 
Intracellular superoxide is produced by means of mitochondrial electron 
chain and cytosolic oxidases, such as NADPH/NADH oxidase or xanthine oxidase 
(Turko, I. & Murad, F, 2002). Aerobic respiration is thought to be the main source 
of ROS in the body.  
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Other sources are peroxisomal beta oxidation of fatty acids, microsomal 
cytochrome P450 metabolism of xenobiotic compounds, stimulation of 
phagocytosis by pathogens, arginine metabolism (Radi, R. 2004). ROS are 
present in very low concentration as compared to that of oxidizable substrate. 
Antioxidants which are found in plasma and soluble in lipoprotein include 
ascorbate, albumin, bilirubin, urate, tocopherols, heamopexin and carotenoids.  
 
Nitric oxide (NO) plays a most important role in many physiological 
processes such as neurotransmission, inhibition of platelet adherence and 
aggression, blood pressure control, neutrophil aggregation, and blood clotting 
(Lupidi, G. et al 1999). In these conditions the concentration of NO keeps 
changing frequently in all parts of the body. NO is produced from L-arginine which 
acts as a substrate of three isoforms of nitric oxide synthase (NOS): neuronal NOS 
(nNOS or NOS-I) originally identified in brain and endothelial NOS (eNOS or NOS-
II) present in endothelial cells. Both nNOS and eNOS require calcium and 
calmodulin as cofactors and generate low amounts of ·NO (Turko, I. & Murad, F, 
2002). A few pathological processes like reperfusion of ischaemic tissues 
stimulate NO production after induction of its third isoform, inducible NOS (iNOS or 
NOS-III), which is basically found in macrophages and does not require calcium or 
calmodulin as co factors (Colasanti, M. & Suzuki, H. 2000). This enzyme 
generates larger amounts of NO than the other two isoforms.  This is thought to be 
the mechanism behind cytokine mediated cardiac contractile dysfunstion and 
development of cardiovascular disease.  
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One of the mechanisms by which excess NO can injure tissues is by its reaction 
with the ROS, superoxide radical (O2-) to give the main end product, the 
peroxynitrite anion (ONOO-), which is a potent nitrating agent (Halliwell, B. 1997). 
However, the role of peroxynitrite to initiate tyrosine nitration in vivo has been 
controversial (Radi, R. 2004). The biological half life of peroxynitrite short (Lupidi, 
G. et al 1999). Being highly reactive it interacts with the proteins near the site of 
generation and cause the covalent modification of several amino acid residues in 
proteins, such as cysteine, methionine, tryptophan and tyrosine residues (Lupidi, 
G. et al 1999). This covalent modification generates 3-nitrotyrosine (3NT) which is 
used as a marker of oxidative damage (Aulak, K. 2003). 
 
1.2 Protein Nitration 
Nitration of the protein tyrosine is thought to be the footprint for in vivo production 
of free radical species (Turko, I. & Murad, F. 2002). It is a post-transational 
modification which occurs in a number of diseases. It alters protein structure, 
function and metabolism and produce dysfunctional changes. It may loose or gain 
an extra function but the general effect is inhibition. Nitration may prevent or 
activate the phosphorylation of tyrosine residues. Protein nitration is involved in 
disease initiation and progression (Turko, I. & Murad, F. 2002). Most commonly, 
oxidative stress can lead to in vivo modification of proteins through nitration of 
tyrosine residues by RNS such as peroxynitrite (Galinanes, M. & Matata, B. 2002) 
and 3NT is the stable end product of such reactions (Shigenaga, M. et al, 1997).  
 
Alternative pathways of protein nitration include oxidation of nitrite by 
peroxidases and hydrogen peroxide. Moreover, some transition metal dependent 
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mechanisms have come to light. They all result in oxidative damage through the 
nitration of tyrosine residues (Radi, R. 2004). Nitrite is known to be the substrate 
for haemoproteins when it is converted to nitrogen dioxide by myeloperoxidase, 
eosinophil peroxidase as well as other haemeproteins (cytochrome P450s, 
myoglobin), which act in tissue oxidant formation and accounts for nitration of 
tyrosine residues (Ischiropoulos, H. 2003). Also, the formation of nitrous acid 
(HNO2) by nitrite acidification leads to the nitration of tyrosine residues in proteins. 
This reaction needs a lower pH (pH< 6.0) and the acid formed is able to nitrate 
protein slowly without requiring superoxide and hydrogen peroxide (Ischiropoulos, 
H. 2003). 
Chemically, nitration is the addition of the bulky nitro group (-NO2) onto one 
of the ortho carbons of the aromatic rings of tyrosine residues (Ischiropoulos, H. 
2003). This lowers the pKa of the phenolic group from about 10 to 7 and therefore 
disrupts the ability of tyrosine to function in electron-transfer reactions and 
maintenance of protein conformation (Tarpey, M. & Fridovich, I. 2001). Not all 
protein tyrosine residues undergo nitration and similarly not all proteins are 
nitrated. This has led to the view that nitration may be a normal physiological 
control mechanism as well as a pathophysiological event.  
 
Tyrosine nitration has been observed as an irreversible process, however 
some studies have stated that protein nitration is reversible and may have a 
regulatory function, therefore enabling protein nitration to have a more dynamic 
physiological role. “Denitrase” activity has been suggested that may remove the 
nitro group from nitrotyrosine in proteins therefore displaying the possibility of a 
repair mechanism, thus signal transduction (Gow, A. et al, 1996).  
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Protein nitration has been postulated to function in cellular signalling events 
analogous to protein phosphorylation and dephosphorylation, resulting in kinase 
activation, which presumes the reversibility of tyrosine nitration (Tarpey, M. & 
Fridovich, I, 2001). It has been shown that peptides and proteins that are nitrated 
on tyrosine residues are poor substrates for tyrosine kinases, possibly due to 
interference between the nitration of tyrosine on the 3-position with the 
phosphorylation of the hydroxyl group on the 4-position (Kamisaki, Y. et al, 1998). 
Therefore the removal of the nitro group by “denitrase” could restore protein 
function and allow them to become substrates for tyrosine kinases and have 
important effects on cell signalling pathways (Kamisaki, Y. et al, 1998).  
In pathophysiology, evidence suggests that most of the cardiovascular 
disease is the result of the high production of these free radicals and reactive 
species in the body and features the accumulation of nitrated proteins on one or 
other site depending on the type of disease such as cardiovascular inflammation, 
atherosclerosis, autoimmune myocarditis, heart failure, ischaemia reperfusion 
injury as well as many more (Turko, I. Murad, F. 2002). The pro and 
antiatherogenic role of NO has been broadly studied. Its pro atherogenic role can 
be described by the modification of lipids caused by RNS/ROS derived from NO 
metabolism. Protein tyrosine nitration was found to be associated with iNOS 
expression and confirmed iNOS positive in macrophage lesions at various stages 
of atherosclerosis. A study has revealed the tyrosine nitration of prostacyclin 
synthase on bovine atherosclerotic arteries on the very early early stage when 
arteries are thickened without any signs of necrosis and rupture of plaques.  
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Inactivation of prostacyclin synthase may predispose further platelet aggregation 
and thrombus formation. Intermittent claudication may be one of the 
consequences of severe atherosclerosis and protein nitration.  
 
1.3 Intermittent Claudication (IC) 
 Claudication is basically a circulation problem which causes pain in the lower 
limbs while walking, as the muscles need more oxygen. The circulation becomes 
normal on resting. This condition features the presence of cholesterol and other 
fatty deposits in the arteries which narrows them and reduces the blood flow due 
to the presence of these atherosclerotic plaques (Tarpey, M. & Fridovich, I, 2001). 
The pain is experienced in the thigh and calf. It is known to be the symptom of 
peripheral arterial disease (PAD) and also known as “hardening of arteries” or 
atherosclerosis, which is a precursor to IC. Claudication pain is intermittent as it 
comes and goes. It prevails on exercise with the increased oxygen demand and 
tends to decrease when the person starts resting. In case of severe artery 
blockage the pain is experienced even in the rest condition. Partially clogged 
arteries are able to deliver enough blood and oxygen at rest but during exercise 
the need for oxygen outweighs the supply and causes pain (Stewart, A. & Lamont, 
P, 2001). ROS are potentially concerned in atherosclerosis by contributing to the 
oxidative damage of low density lipoprotein (LDL), which is a critical event, in the 
development of the atherosclerotic plaque (White, R et al, 2004). This oxidation 
takes place at almost all the sites of inflammation. One event is the formation of 
peroxynitrite which initiates oxidation and forms 3NT. 
.  
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1.4 Apolipoprotein A1 
Protein constituents of lipoproteins are known as apolipoproteins. In plasma, they 
are found in high density lipoprotein (HDL) which functions to remove the 
cholesterol from the tissues and drain it back into the liver. It has been 
demonstrated that measurement of various forms of apolipoproteins can improve 
the prediction of risk of cardiovascular disease (Walldius, G & Junger, I, 2004). 
Lipoproteins are made up of a lipid core of cholesterol ester which is surrounded 
by a coat of cholesterol, phospholipids and Apolipoprotein (figure 1.2). Apo A1 is 
synthesised in the liver and small intestine and is the cofactor for lecithin 
cholesterol acyltransferase (LCAT) which is responsible for the syntheis of most of 
the plasma cholesteryl esters. The exact mechanism of action of apo A1 is not yet 
understood but it actively stimulates the cholesterol removal from cells and has an 
antioxidant ability which prevents some of the inflammatory damage in 
atherosclerosis. The anticlotting effect of apo A1 has been demonstrated by its 
isolation as a prostacyclin (PGI2) stabilising factor (Yui, Y et al, 1988). 
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Figure 1.2 Structure of apolipoprotein A1 (Gurgel, E.F. et al, n.d) 
 
Apolipoprotein A occurs in two major forms, apo A1 and apo A2. But it is apo A1 
which is found in abundance and plays a very important role in HDL metabolism. 
Apolipoprotein A1 is the chief constituent of HDL and acts as the primary acceptor 
of the unesterified cholesterol from the peripheral tissues (Eckardstein, A et al, 
2001). It occurs as a single polypeptide chain of 243 amino acids residues 
(Sasaki, J. et al, 2000).  
 
It has been reported that apo A1 not only inhibits the inititation and 
progression of atherosclerosis but also makes the pre-exisisting atherosclerotic 
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lesions regress (Sheng, Wu et al, 2005). Apo A1 and apo B carry cholesterol in the 
blood stream. But apo B is cholesterol donor found in low density proteins (LDL) 
and apo A1 is cholesterol scavenger found in HDL. 
 
LDL cholesterol is a very critical feature in the development of atheroma. 
HDL is involved in its reverse transport to the liver and hence is Anti-atherogenic 
(Lupidi, G. et al, 1999). Cholesterol is an essential component of the cell. The bile 
acids are manufactured in the hepatocytes from cholesterol, and finally it is 
excreted from the body in the form of bile. Its presence must be controlled to 
maintain the body homeostasis. If the cells are unable to give up the free 
cholesterol (FC), it is stored as esterified cholesterol (EC). The cholesterol is 
transported to the cells as low density lipoproteins (LDL) (Aulak, K. et al, 2001). 
The LDL receptor (LDL-R) present on the cells is controlled by a negative feed 
back mechanism. Increased cholesterol level tends to suppress the transcription of 
LDL-R which in turn delays the LDL clearance. If the cholesterol level is 
decreased, the transcription is induced which maintains the feed back mechanism 
(Aulak, K. et al, 2001). 
 
At the commencement of metabolism, a cholesterol-poor HDL particle, 
which has apo A1, acquires cholesterol and phospholipids from peripheral cells. 
This is facilitated by adenosine triphosphate-binding cassette protein-1 (ABCA1), 
beginning a process known as reverse cholesterol transport (RCT) (figure 1.3). 
Now, the cholesterol within the HDL particle is esterified by LCAT and this 
esterified cholesterol is ultimately taken up by the liver through the scavenger 
receptor typeB1 (Ballantyne and Nambi, 2004). 
  Apolipoprotein A1 and Polymorphisms                                                                                                                                                                  
  Sumit Bhagat 
12 
 Cholesteryl ester transfer protein (CETP) replaces the cholesteryl ester in HDL by 
triglyceride from other proteins. Levels of apo A1 are strongly linked with those of 
HDL-cholesterol, and, as a result the expression of apo A1 may be responsible for 
determining the plasma level of HDL.  
 
 
Figure 1.3 Schematic representation of the role of the ABCA1 lipid transporter in 
HDL biogenesis and reverse cholesterol transport. (Tontonoz and Mangelsdrof, 
2005) 
 
 In addition to reverse cholesterol transport, HDL might protect against 
atherosclerosis by preventing oxidation of LDL and promoting the availability of 
nitric oxide, and modulating expression of endothelial cell adhesion molecules 
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(Ballantyne and Nambi, 2004). Yamato, K et al, 2005, suggested the possible links 
between HDL and apo A1 metabolism and atherosclerosis in patients with type 2- 
diabetes. Elevated serum LDL and depressed HDL in conjugation with elevated 
triglycerides (Tg), are well known risk factors for CVD. HDL-2 is the largest particle 
amongst all of HDL particles, which contains the most lipids in the core. And, pre β 
HDL is of the smallest size and active in taking up the peripheral cholesterol.  
 
1.5 Mutants of Apolipoprotein A1 
The gene that encodes apolipoprotein A1 is basically located on chromosome 
11q23-q24 with two other apolipoprotein genes; apo C3 and apo A4 (figure 1.4).  
The coding region is in red and the untranslated region in blue. 
 
 
Figure 1.4 Genomic region of apo A1 gene.  
      The apo A1 gene has three introns: IVS-1, IVS2 and IVS-3. The first 
interruption, IVS-1 is 197bp long and exists in the 5’ untranslated region between 
bases 20 and 21 upstream of the codon for methionine (Met) which initiates 
translation. IVS-2 is 186bp long and occurs in the codon specifying amino acid 10 
which is in the apo A1-prepeptide. The third sequence, IVS-3 is 588bp long and 
interrupts the codon specifying amino acid 43 of the mature protein. Most of the 
propeptide is present in exon 2 while exon 3 contains propeptide and amino 
terminus.  
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Exon 4 has codons for 200 amino acids which consist of COOH- terminal part of 
the molecule. It consists of six highly homologous 66bp long tandem DNA repeats. 
Upstream of the apo A1 transcription start site is a 7bp long AT-rich region which 
is probably the TATA box (Breslow, J.L, 1985).   
Decreased concentrations of HDL cholesterol and apo A1 have been 
demonstrated because of the various mutations in apo A1. The mutations result 
into premature atherosclerosis, corneal opacities and xanthomatosis. The 
coronary risk was higher in cases where no plasma apo A1 was identified. But in a 
couple of cases no increased risk for myocardial infraction could be demonstrated 
(Assman sited in Rosseneu, 1995). In 1995, Lackner demonstrated a proband aws 
associated with developing early coronary artery disease with a deletion of apo 
A1, C3 and apo A4 gene.  
Additionally, a Turkish girl was was found to have no detectable apo A1 
when she was affected by HDL deficiency with xanthomas. Karathanasis 
described coronary artery disease associated with an inversion of 5.5 kb in the 
apo A1/C3 gene. The truncation of apo A1 at residue 230 leads to corneal opacity 
and LCAT deficiency. The deletion of residues 145-160 results in HDL deficiency and 
xanthomas. A deletion in intron 2 causes coronary heart disease. Defects in this 
gene are linked with HDL deficiencies, including tangier disease, and with 
systemic non neuropathic amyloidosis.  
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Apo a1 Milano is an apo a1 mutant which was found in an Italian 
community from Limone on the shore of Lake Garda. The prominent feature of this 
molecular abnormality was hypoalphalipoproteinemia but without atherosclerosis 
or any risk of coronary heart disease. The presence of this mutation allowed the 
existence of an additional cysteine bridge which makes possible homodimer or 
heterodimer formation with apo a2. This mutation leads in some cases to impaired 
cholesterol esterification in HDL together with decreased LCAT activity.  
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Despite very low HDL cholesterol levels, no premature vascular disease 
has been found in apo A1 (Milano) carriers (Parolini C. et.al, 2005). A single amino 
acid mutation was found during an electrophoretic mutation screening of 32,000 
new borns from Germany. They were presnt in the primary structure of apoA1 and 
are P165-R, P143-R, and K107 (Eckardstein, A. et al, 1990). A naturally occurring 
point mutation, V156E, is linked with extremely low plasma apo A1 and HDL levels 
and coronary heart disease (Kyun, H. and Jonas, A., 2000). HDL might protect 
against atherosclerosis by preventing low density lipoprotein oxidation and 
promoting the availability of NO (Ballantyne and Nambi, 2004). 
 
The extent of atherosclerosis is determined by the size of lipoprotein 
particles, small LDL particles being more atherogenic and the patients have quite 
a few of the large HDL particles as compared to the healthy individual, and the 
severity of the disease increases as their number increases. (Gualberto R. et al) 
The reason behind the size variation and its effects has not yet been understood. 
It has been reported that a genetic variant in the apo A1 promoter alters the 
response of small and large HDL particle distribution to exercise training (Kouji, K. 
et al). A 75G/A single nucleotide polymorphism (SNP) has been demonstrated in 
apo A1 gene which is linked with HDL-C concentrations to dietary changes in 
polyunsaturated fat intake. 53 subjects were found to be G homozygotes (G/G) 
and 22 were A carriers (A/G and AA), when these 75 subjects were genotyped for 
75G/A SNP. This genetic variation at the apo A1 gene promoter is linked with HDL 
redistribution resulting from exercise training (Ruano, G. et. al, 2006). In a recent 
study apo A1 has been demonstrated as a selective target for myeloperoxidase-
catalyzed oxidation modification in human atheroma (Zheng L. et al, 2004).  
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HDL islolated from human atherosclerotic lesions and the blood of the 
patients with coronary artery disease were found to have elevated levels of 3-
chlorotyrosine. Moreover, Tyr-192 was reported to be the major site which is 
chlorinated in apo A1 which is directed by lysine residues. As a result, the 
chlorinated apo A1 loses its facility to promote cholesterol efflux from cells by the 
ABCA1 pathway. On the other hand, methionine residues inhibit this chlorination 
and act as a local protein bound antioxidants. So, the combination of tyrosine 
chlorination and methionine oxidation might help apo A1 to maintain its functional 
state. They also suggested the modification of a limited number of amino acids 
occur during the oxidative damage of apo A1 and the oxidation-resistant forms of 
apo A1 have enhanced anti atherogenic activity in vivo (Shao, B. et al, 2006). 
 
Mutations in ABCA1, which functions as a cholesterol efflux regulatory 
protein (Nan, W. et al, 2001), causes very low concentrations of HDL-C and apo 
a1 resulting in Tangier disease. The LCAT and the apo a1 were studied in 
unrelated French Canadian probands by direct sequencing to analyse the 
molecular causes of severe HDL cholesterol deficiency. A novel nonsense apo a1 
mutation known as E136 was detected in a few subjects. They observed the 
segregation of the apo a1 locus and the defined mutation is a cause of HDL-C 
deficiency and related with premature coronary artery disease in the specified 
population. (Zari, D. et al, 2005)  
 
Hoving, Gk. et al has demonstrated a novel mutation, L178P, in the apo A1 
gene which leads to an endothelial dysfunction, increased arterial wall thickness 
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and finally premature coronary artey disease. Due to a limited number of carriers 
of the apo A1 defects, data on the consequences of such defects have remaines 
injustified and inconclusive. 
 
1.6 Current project  
Mercer, S. at Coventry University, in her previous study of claudicant patient’s 
plasma, found some of the proteins nitrated including apo A1, which actually helps 
in removal of cholesterol and other fatty deposits from the tissues. The subjects 
were patients at a clinic at New Cross Hospital, Wolverhampton and the controls 
were university students and staff members. The nitration of ApoA1 in claudicant 
patients could possibly be because of mutations in ApoA1 which increases their 
risk of predisposition to atherosclerosis. It was therefore necessary to know the 
spectrum of mutations in ApoA1 gene in normal healthy control population to draw 
any inferences about association of mutations in ApoA1 with artherosclerosis in 
claudicants. With this broader aim, the present study focussed on investigating 
mutation profile of ApoA1 gene in normal healthy controls. The possibility was 
raised that claudicants may have a mutation in the apo A1 gene which 
predisposes them to atherosclerosis. Sequence information would be necessary to 
determine this and the current project was to establish the protocols in the DNA of 
control subjects. This is achieved by the amplification of the three main exons and 
three introns along with the 5’ and 3’ flanking regions, followed by sequencing of 
the amplicons. PCR and fluorescent DNA sequencing were the only methods used 
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2.1 Sample Collection 
To ensure the efficiency of the PCR process, the saliva samples were collected 
from only one subject. Afterwards eight samples from different subjects were 
gathered by spitting in a tube. The sample volume was 2 ml and all of them were 
double-blind. Saliva sample was stored at 4°C as soon as they were collected. 
Samples which were to be used again were stored frozen at -80°C. All samples 
were processed as described below. 
 
2.2 DNA Extraction from Sample 
The Generation DNA purification system with the Generation Capture Column Kit 
from Gentra Systems was used for DNA-purification. The dry block heater was  
pre heated to 99°C. A Generation Capture Column contained in a blue Waste 
Collection Tube, an additional blue Waste Collection Tube and one clear DNA 
Collection Tube was assembled to process each sample. 200µl well mixed sample 
was inserted into the Capture Column whilst gently touching the centre of the 
matrix with the pipette. Samples were permitted to absorb at room temperature for 
at least one minute or up to an hour. The recommended time is 15 minutes. 
Afterwards, 400µl DNA Purification Solution (Solution 1) was added and incubated 
for one minute at room temperature. Solution started draining into the Waste 
Collection Tube during the incubation time. The sample was then centrifuged for 
10 seconds at 12,000 x g. A waste volume of 600 µl was collected in the blue 
Waste Collection tube. 
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The Generation Capture Tube was transferred to the second blue Waste 
Collection tube. Another volume of 400 µl DNA Purification Solution (Solution 1) 
was added and incubated for one minute at room temperature. The centrifugation 
was repeated in the same manner as earlier.  A waste of 400 µl was collected. The 
matrix was white or nearly white. 200 µl of DNA Elution Solution (Solution 2) was 
added and no incubation was done at this point. After centrifugation as described 
above 200 µl waste volume was collected. The matrix containing the purified DNA 
was white. 
 
2.3 Sample Elution 
The General Capture Column was transferred to a clear DNA Collection Tube and 
the second blue Waste Collection Tube containing 600 µl was discarded.  
200 µl DNA Elution Solution (Solution 2) was added was allowed to incubate in a 
dry block heater pre heated to 99°C. The tubes were placed in such a manner that 
the Generation Capture Column was completely enclosed within the heat block to 
ensure proper heating of the sample. Immediately after heating, the sample was 
centrifuged for 20 seconds at 12,000 x g to free the purified DNA from the  
Generation Capture Column. The collected 200 µl DNA solution appeared clear. 
The Generation Capture Column was now discarded. The purified DNA was now 
ready for analysis. 
2.4 DNA Storage 
Purified DNA was stored for up to three months at 4°C. For long term storage, it 
was stored at –20°C.  
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2.5 DNA Quantification  
Nucleic acid samples require purification prior to measurement to ensure accurate 
results. DNA isloated from organisms is tightly bound to the protein present within. 
It is not always possible to get rid of the protein component. To determine the 
concentration and purity of the DNA solution, the absorbance of UV light is 
measured in a spectrophotometer. Both DNA and protein absorb UV light and give 
different absorbance maxima, which are at 260 nm and 280 nm respectively. In an 
absorption spectrum, both curves slightly overlap in the areas including 260 nm 
and 280 nm. Absorbance at 260 nm is mainly due to the DNA but a little bit by the 
protein. At 280 nm it is the other way round. By dividing the two absorbance 
values the purity of the DNA solution is calculated. If the DNA solution is 
substantially free of protein, the 260/280 nm ratio will be high . A ratio of ~1.8 is 
generally accepted as 
“Pure” for DNA; a ratio of ~2.0 is generally accepted as “pure” for RNA. Small 
changes in the pH of the solution will cause the 260/280 nm ratio to vary. Acidic 
solutions will under represent while the basic solutions will over represent this ratio 
by 0.2-0.3 (Technical Support Bulletin, 2007). The 260/230 nm ratio is used as a 
secondary measure of nucleic acid purity. The 260/230 values for “pure” nucleic 
acid are often higher than the respective 260/280 values. Expected 260/230 
values are commonly in the range of 2.0-2.2(Technical Support Bulletin, 2007). If 
the ratio is appreciably lower than expected, it may indicate the presence of 
contaminants which absorb at 230 nm. 
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Nanodrop, a small scale spectrophotometer was used for the DNA quantification. 
The apparatus is a cuvette-less fibre optic spectrophotometer with a 1mm light 
path which allows it to utilize even very small volumes of sample(1-2µl). The 
concentration and the purity of the sample were determined with this method. 1µl 
of DNA sample was positioned on the Nanodrop platform and an absorption 
spectrum from 320 nm to 230 nm was measured.  
 
2.6 Polymerase Chain Reaction of ALU-TPA 
The human genome contains a number of repetitive DNA sequences. These occur 
as tandem repeats (satellites, micro satellites or minisatellites) or as dispersed 
repeats (transposable elements), including LINEs (long interspersed nuclear 
elements) and SINEs (short interspersed nuclear elements). One class of SINE 
found in human genome is the ALU element.  
 
In this experiment, the polymerase chain reaction (PCR) is used to amplify a 
nucleotide sequence from chromosome 8 to look for an insertion of a short DNA 
sequence called Alu within the tissue plasminogen activator (TPA) gene. These 
sequences are 280-bp long and are named Alu as they contain the recognition 
sequence for the restriction enzyme AluI. There are about 1 million Alu elements in 
the human genome, and they are known to have arisen very early in the course of 
human evolution. However some Alu elements have subsequently been lost from 
the genome and the modern human population frequently shows dimorphism 
(either Alu is present or absent) for particular Alu elements.  
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Alu elements analysed by PCR using primers complementary to unique DNA 
sequences flank (lie either side of) the Alu sequence. The length of the PCR 
product indicates whether Alu is present or absent. One such Alu element, called 
TPA-25, is found within an intron of the tissue plasminogen activator gene. This 
insertion is dimorphic. In this experiment, oligonucleotide primers, flanking the 
insertion site, are used to amplify a 400-bp fragment when TPA-25 is present and 
a 100-bp fragment when it is absent. Each of the three possible genotypes—
homozygous for the presence of TPA-25 (400-bp fragment only), homozygous for 
the  absence of TPA-25 (100-bp fragment only), and heterozygous (400-bp and 
100-bp fragments) are distinguished following electrophoresis in agarose gels.  
To test the efficacy of the DNA extraction and PCR process, PCR on an ALU 
element in an obtained human genome sample was carried out during the first 
week of experimentation. It confirms the performance of the sample and PCR 
buffer. The latter contains: 
10mM KCl, 
10mM (NH4)2SO4, 
20mM Tris HCl,pH 8.8, 
2mM MgSO4, 
0.01% TritonX-100, 
Furthermore, a forward primer TPA25F 0.5µM (5’ GAT AGA GTT CCG TAA CAG 
GAC AGC T 3’), a reverse primer TPA25R 0.5µM (5’CCC CAC CCT AGG AGA 
ACT TCT CTT T 3’) and dNTPs 200µM each were added to the buffer to make the 
master mix. If they are used in excess, they may reduce the fidelity.                      
Also, the freeze/thaw cycle is destructive. Hence, dNTPs, templates and Taq 
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polymerase (source: Invitogen) were aliquoted on arrival. The tubes to be used in 
the experiment were allowed to incubate at 95°C for 5 minutes. Finally 2µl Taq 
polymerase (1 unit) was added to each tube and mixed.  
 
Subsequently, the tubes were set in the thermal cycler for amplification. The 
conditions used for the process were 30 cycles at 94°C for 1 min, 58°C for 2 min, 
and 72°C for 2 min, and a concluding incubation at 72°C for 8 minutes. The PCR 
products obtained were analysed by gel electrophoresis. Free Mg2+ are required 
by Taq polymerase for its performance. The amount of free Mg2+ can be reduced 
by template DNA, chelating agents (e.g. EDTA), dNTPs (0.8mM MgCl2 complexes 
with 0.2mM dNTP) and protein. So 1-4mM was tested for each primer set. MgCl2 
solution tends to make up a concentration gradient when frozen, so it was 
defrosted completely and vortexed before use.  
 
2.7 Polymerase Chain Reaction (PCR) of the selected regions of the Apo A1 gene 
Primers were found for all the exons and introns of the candidate gene. Web 
Primer, was used to define the primer pairs. The primer pair should not anneal 
with each other in any condition and have the reasonable G/C contents (<40%). 
Blast from NCBI was used to analyse the PCR fragment matches with the original 
gene sequence. Once the primer pairs were selected for all the exons and introns, 
they were ordered from Invitrogen. The PCR amplification of gene specific regions 
was carried out in 25 µl of reaction volume by using 25- 150 ng genomic DNA as a 
target. A master-mix (MM) was made to run every PCR. The composition of the 
PCR master mix(100µl) is listed below in Table 3. 
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                                  Table 1: Components of the reaction mixture 
All the reaction mixtures were set up in an area separate from that used for DNA 
preparation or PCR product analysis. The solutions were completely mixed before 
use in order to avoid any localised concentration of salts.  
The master mix typically contains all of the components for PCR excluding the 
template DNA. A volume of master mix was prepared which was 10% greater than 
that required for the total number PCR assays to be performed. A negative control 
(without template DNA) was always included in the PCR reaction. This was done 
to check if there is any contamination in the template DNA.   
The master mix was mixed properly and dispensed in appropriate volumes into the 
PCR tubes. The template DNA was added to the individual tubes containing the 
master mix. Thermal cycling was performed on PTC-100 Programmable Thermal 





Master Mix (100µl) 
Sterile Water - - 84µl 
PCR Buffer 10x 1/10 dilution 2.5µl 
dNTP 10mM 200µM 2.3µl 
MgCl2 25mM 1mM 2µl 
Primer A 
(reverse) 
0.5µM 10.5pmol/μl 4.8µl 
Primer B 
(forward) 
0.5µM 12pmol 4.8µl 
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30 cycles of 94°C for 1 minute.  Annealing at a temperature( different for the gene 
regions amplified) for 2 min and a final extension at 72°C for 5 minutes.  
For the “hot start” PCR, the tubes were incubated for 5 minutes just after the 
centrifugation. One unit (2µl) of taq polymerase was added after the hot start and 
centrifuged. The PCR program was started and the PCR tubes were added once 
the thermal cycle reached the initial 94°C. After amplification, samples were stored 
overnight at -20°C for long term storage. The primer sequences used with the 
standardized PCR conditions are listed in the table below.  
 









Exon1- Intron A 
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Exon 4 












     Table 2: Primers used for the standardised PCR reactions 
 
2.8 Primer design 
 The primers were designed and ordered by the supervisory team. A computer 
programme called ‘Web Primer’ (Stanford University,California.) was used to 
design primers for the PCRs undertaken. The length and the content of the 
primers were taken into consideration. The primer pairs do not anneal with each 
other and have a reasonable G/C content, which is less than 40%. Web Primer is 
to be found on http://genome-www2.stanford.edu/cgi-bin/SGD/web-primer. The c-
DNA sequence was used without the polyA tail.  
The polyA tail prevents the program finding a good primer pair because it will look 
for primer sequences with some minimum value of G/C content- not 0% as it 
would be the case for oligoT.  
 
The cDNA sequence is submitted. The search was started within upto 50 bases 
from the 5’ end and 3’ ends. The best pair is examined and copied to the clipboard 
and edited in MS WORD. It can be analysed by BLAST, where exactly the PCR 
fragment matches on the original DNA. After searching for all the exons and 
introns, the primer pairs were ordered from Invitrogen.  
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The homepage http://www.ncbi.nlm.nih.gov/gquery/gquery.fcgi was used to find 
the m-RNA sequences of Apo A1 and as well as the gene sequence.  
 
 
To locate any variation in the sequences of Apo A1 exons, restriction enzymes are 
needed. First of all, the cDNA sequence of Apo A1 is needed. For finding this 
sequence NCBI ENTRZ was used (www.ncbi.nlm.nih.gov/Entrez). The nucleotide 
sequence database could be browsed for the complete Apo A1 m-RNA entry by 
searching for “Homo-sapiens Apolipoprotein A1 m-RNA” or for the GI number 
4557320. Once the correct m-RNA is found, the FASTA report display is required. 
This sequence is used for the restriction analysis. Afterwards, Web-Cutter 
(www.firstmarket.com/cutter/cut2.html) was used to find restriction enzymes. By 
following the instructions on the homepage all endonuclease were displayed. 
 
2.9 Optimisation of PCR 
The PCR conditions for ALU TPA were derived from the previous studies held in 
the university laboratory. Initially similar PCR conditions were used for the Apo A1 
gene and gradient PCR’s were designed later to find out the correct annealing 
temperature for the specific regions of the gene to be amplified. 
 In the beginning, none of the PCRs seemed to be working. The primer 
concentration was lowered to one tenth and one fifth . But no positive outcomes 
were gained. The control sample (without DNA template) was run with every PCR 
to ensure there was no contamination in the samples. Earlier, the control sample 
was found contaminated for some PCRs as it consistently showed a product band. 
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To overcome this, fresh reaction mixture was prepared and the reaction was done 
again. The DNA concentration was different for every sample. Samples with high 
concentration were diluted before use.  
 
Gradient PCR with a annealing temperature gradient of 57±7°C was set up to find 
out the correct annealing temperature for the three exons of APO A1 gene. The 
temperature range in the PCR machine counting from first well till twelfth well was 
between 49.9°C and 64.5°C (TABLE). The PCR program is shown in TABLE.  
 
        Well 1 2 3 4 5 6 7 8 9 10 11 12 
Temperature[°C] 49.9 50.1 50.8 52.2 53.8 57.8 58.1 59.7 60.5 61.2 62.5 63.2 
             Table 3: The Temperature in each well in a gradient PCR machine 
 
 
Step Temperature Time Cycles 





2 57°C                           2 min 
Midpoint Gradient 
 
R= 2°C /s    G= ±7ºC 
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4 72°C 5 min 1x 
5 22°C Hold  
          
            Table 4: PCR program for APO A1; G= gradient 57°C ±7°C; R= ramp time 
 
2.10 Gel Electrophoresis 
After the PCR, gel electrophoresis was performed. Initially, for Alu PCR products, 
2µl ethidium bromide (5mg/ml) was added to 35ml of 2% molten agarose. This 
molten agarose was then poured into gel apparatus and left to set on the bench. 
Once it is set, the running buffer (1 x TBE) was dispensed on  top of the gel.  TBE 
(Tris-Borate-EDTA) is a buffer solution which consists of Tris base, boric acid, 
EDTA and water.  
 
Bromophenol blue loading buffer (10µl) was added to each PCR tube, mixed and 
centrifuged. The sample DNA was loaded into the wells of the gel. The power pack 
Shandon Vokam 400 was used and a current of 50mA was passed through the 
gel, until the bromophenol blue reached close to the anode. Furthermore, for the 
electrophoresis of the apo A1 amplicons a kit from Cleaver Scientific Ltd Multi Sub 
Horizontal Agarose Gel Electrophoresis Systems was used.  The gel was then 
stained in EtBr (final concentration of 0.5 g/ml) for one hour and visualized under 
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UV illumination. A marker (table 2) was loaded on each side of the gel using 1µl of 
marker, 9 µl sterile water and 5 µl bromophenol blue for one well.  
 
Ethidium bromide is known to be a potent mutagen. Then all the solutions 
and gel containing EtBr were handled very carefully. A lab coat and the gloves 
were worn worn all the time during the experiment and the process waste and 
contaminated solutions were disposed of in an activated charcoal bucket.  
 





1 766 62ng 
2 500 40ng 
3 300 48ng 
4 150 61ng 
5 50 89ng 
                          Table 5: PCR marker used for Gel-electrophoresis 
 
2.11 Sequencing  
The Plasmid to Profile service of The Functional Genomics Laboratory in the 
University of Birmingham provides a custom sequencing service based on 
fluorescent Sanger sequencing. The amplicons were isolated using a 
recommended kit, quantified and sent with the primers to the laboratory. The 
amount of PCR products used for sequencing was 5 – 10 ng. The products were 
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split into two tubes and 3.2 pmol of either forward or reverse primer was added. 
Finally, the samples were sent to the laboratory for sequencing. PCR amplified 
samples were treated with Exonuclease-I and Shrimp alkaline phosphatase 
enzyme (1X SAP buffer, 1U of SAP enzyme and 0.5U Exo-I enzyme). Mixture was 
incubated at 37°C for one and a half hour and enzyme was inactivated at 70°C for 
15 min. The automated cycle sequencing of PCR amplified samples was carried 
out with specific primers used for PCR-amplification and universal sequencing 
primers using dye terminators (ABI PRISM Big Dye terminator cycle sequencing 
ready reaction kit). Ten microliter of Sequencing reaction was prepared (1X buffer, 
0.125X Big Dye V 3.0 Ready Reaction mix, 0.4μM of primer and 10ng of well 
quantified sample) and pipetted into each well of a 96 well plate and cycle 
sequencing was performed under standard conditions as follows. 
 
Rapid thermal ramp to 96°C 
96°C for 10 seconds 
Rapid thermal ramp to 50°C 
50°C for 5 seconds 
Rapid thermal ramp to 60°C 
60°C for 4 min 
Step 2 to 6 were repeated for 25 cycles 
Samples were kept at 4°C until precipitation. 95% of ethanol was added to each 
well at a final concentration of 60 ± 3 % and sealed with strip caps. The plate was 
inverted few times to mix properly and left at RT for 15 min to precipitate the 
extension products. Plates were centrifuged at 2000x g for 20 min. Supernatants 
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was discarded by inverting the plate onto a paper towel. The pellets were washed 
with 150μl of 70% ethanol and centrifuged at 2000x g for 10 min. Washing with 
70% alcohol was repeated once more.  
 
Supernatant was removed by inverting the plates onto a paper towel. Plates were 
centrifuged in inverted position once at 700x g for 1 min to remove the residual 
ethanol. 10 μl of HiDi formamide was added to each well and samples were 
denatured at 95ºC for 4 min. and chilled immediately. Plates were placed on an 
AutoSampler for sequencing. The samples were electrophoresed on an ABI Prism 
3100 Avant Genetic Analyser. 
Fluroscence electropherogram results were obtained by e mail and were 





























  Apolipoprotein A1 and Polymorphisms                                                                                                                                                                  
 
  Sumit Bhagat 
34 
 
3.1 PCR primer selection with Web primer 
The primers were designed for all the three exons and four introns of the apo A1 
gene using Web Primer program. The gene sequence of apo A1 is given below. 
Various colour patterns have been used to distinguish the primer sequences used 
to amplify different regions of apo A1 gene. The forward and reverse arrows 
indicate the forward and reverse primers used to amplify the respective regions. 
 
 5’ END 
1        tctccctgga atgctggtgg tgggggaggc agtctccttg gtggaggagt cccagcgtcc 
61      ctcccctccc  ctcctctgcc  aacacaatgg  acaatggcaa ctgcccacac  actcccatgg 
121    aggggaagg gatgagtgca gggaaccccg  accccacccg ggagacctgc aagcctgcag 
181    acactcccct cccgccccca ctgaaccctt gacccctgcc ctgcagcccc cgcagcttgc 
24    tgtttgccca  ctctatttgc   ccagccccag  ggacagagct gatccttgaa  ctcttaagtt 
301   ccacattgcc aggaccagtg agcagcaaca gggccggggc tgggcttatc agcctcccag 
361   cccagaccct ggctgcagac ataaataggc cctgcaagag ctggctgctt agagactgcg  
421    agaaggaggt gcgtcctgct gcctgccccg gtcactctgg ctccccagct  
471   caaggttcag gccttgcccc aggccgggcc tctgggtacc tgaggtcttc tcccgctctg  
531   tgcccttctc ctcacctggc tgcaatgagt gggggagcac ggggcttctg catgctgaag 
591   gcaccccact cagccaggcc cttcttctcc tccaggtccc ccacggccct tcaggatgaa 
651   agctgcggtg ctgaccttgg ccgtgctctt cctgacgggt aggtgtcccc taacctaggg 
711 agccaaccat cggggggctt tctccctaaa tccccgtggc ccaccctcct gggcagaggc 
771 agcaggtttc tcactggccc cctctccccc acctccaagc ttggcctttc ggctcagatc 
831 tcagcccaca gctggcctga tctgggtctc ccctcccacc ctcagggagc caggctcggc 
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951 ctgtgtacgt ggatgtgctc aaagacagcg gcagagacta tgtgtcccag tttgaaggct 
1011 ccgccttggg aaaacagcta aagtaaggac ccagcctggg gttgagggca ggggtagggg 
1071 gcagaggcct gtgggatgat gttgaagcca gactggccga gtcctcacct aatatctgat 
1131 gagctgggcc ccacagatgg tctggatgga gaaactggaa tgggatctcc aggcagggtc 
1191 acagcccatg tcccctgcaa aggacagacc agggctgccc gatgcgtgat cacagagcca 
1251 cattgtgcct gcaagtgtag caagcccctt tcccttcttc accacctcct ctgctcctgc 
1311 ccagcaagac tgtgggctgt cttcggagag gagaatgcgc tggaggcata gaagcgaggt 
1371 ccttcaaggg cccactttgg agaccaacgt aactgggcac tagtcccagc tctgtctcct 
1431 ttttagctcc tctctgtgcc tcggtccagc tgcacaacgg ggcatggcct ggcggggcag 
1491 gggtgttggt tgagagtgta ctggaaatgc taggccactg cacctccgcg gacaggtgtc 
1551 acccagggct cacccctgat aggctggggc gctgggaggc cagccctcaa cccttctgtc 
1611 tcaccctcca gcctaaagct ccttgacaac tgggacagcg tgacctccac cttcagcaag                      
1671 ctgcgcgaac agctcggccc tgtgacccag gagttctggg ataacctgga aaaggagaca 
1731 gagggcctga ggcaggagat gagcaaggat ctggaggagg tgaaggccaa ggtgcagccc 
1791 tacctggacg acttccagaa gaagtggcag gaggagatgg agctctaccg ccagaaggtg 
1851 gagccgctgc gcgcagagct ccaagagggc gcgcgccaga agctgcacga gctgcaagag 
1911 aagctgagcc cactgggcga ggagatgcgc gaccgcgcgc gcgcccatgt ggacgcgctg 
1971 cgcacgcatc tggcccccta cagcgacgag ctgcgccagc gcttggccgc gcgccttgag 
2031 gctctcaagg agaacggcgg cgccagactg gccgagtacc acgccaaggc caccgagcat 
2091 ctgagcacgc tcagcgagaa ggccaagccc gcgctcgagg acctccgcca aggcctgctg 
2151 cccgtgctgg agagcttcaa ggtcagcttc ctgagcgctc tcgaggagta cactaagaag 
2211 ctcaacaccc agtgaggcgc ccgccgccgc cccccttccc ggtgctcaga ataaacgttt 
2271 ccaaagtggg aagcagcttc tttcttttgg gagaatagag gggggtgcgg ggacatccgg 
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2391 ccgtgcccag actggacgtc ttagggccaa gatcgacgtt ggaggacctg ctggacgcct 
2451 ggctgcttac gagtgaggga gtagagtctg ccttagcaag gctcaagtag aaaggaagtc  
2511 acagcggacc aggcaaagcc acagacaatc caaggccagg tgccctgaaa ggggctcaaa  




            5’ flanking primers;    19merF, 20merR   330bp amplicon 
            Exon 1 / Intron A;      19merF, 18merR   348bp amplicon 
            Exon 2 / 3 Intron B;    18merF, 21merR   465bp amplicon 
            Exon 3;                 20merF, 21merR   209bp amplicon 
            Intron C;               21merF, 21merR   591bp amplicon 
            Exon 4;                 21merF, 20merR   674bp amplicon    
            3’ flanking;            18merF, 20merR   364bp amplicon          
Figure 3.1 Gene sequence of human apolipoprotein A1. bp = base pairs. 18-
21mer F/R = Forward or Reverse primer. 
 
3.2 DNA purification 
The DNA samples were isolated from university students and staff members. The 
samples were quantified using the Nanodrop spectrophotometer. The best results 
with the polymerase chain reaction can be achieved using 50 -150 ng of template. 
The ratio of absorbance reading at 260/230 nm and 260/280 nm was measured. 
The samples used in the procedure were in the concentration range 24.3 ng/µl to 
150.7ng/µl. The samples with high concentration were diluted. 
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 The 260/280 ratio othe samples signifies that the DNA is not pure, moreover, the 
ratio is also far from the value of 2 at 260/280 nm. The samples were not 
necessarily the same for every PCR.  
 
 








A1 104.0 0.99 1.89 
A2 61.6 0.38 1.51 
A3 98.5 0.65 1.67 
A4 24.3 0.44 1.47 
A5 37.0 0.29 1.31 
A6 53.7 0.37 1.36 
A7 72.9 0.69 1.72 
A8 150.7 0.40 1.43 
A9 85.4 0.35 1.47 
                                  Table 6: DNA extraction results 
3.3 Alu TPA PCR Results 
The results for Alu PCR are shown in the figure 3.1. This control PCR was done to 
ensure the quality of DNA templates and the reaction mix.  Five samples were run 
on the gel along with the control, which does not contain any template DNA. The 
expected bands were of either 400 bp or 100 bp. The markers used were in the 
range of 50 bp to 766 bp.  
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Figure 3.2: Alu TPA PCR gel electrophoresis. A1-A5 = Subjects. The numbers on 
the right of the gel represent the size of the bands of the marker in base pairs (bp). 
Control = no template DNA present. 
 
It can be seen that the two samples A2 and A3 are heterozygous for Alu of 
the tissue plasminogen activator gene, as they have one allele where Alu is 
present with a 400bp band and the other without Alu giving a 100bp band. 
However, the samples A1 and A4 seem to be homozygous as they only have a 
band of 400 bp. It is difficult to explain the bands obtained from sample A5 as 
there is a very intense band at 400bp but a more intense an extra primer dimer 
band at 50 bp than that found in A1-A4. Overall, it can be said that the extracted 
DNA is suitable for PCR and that the other reagents in the mix are functioning. 
 
3.4 Optimisation of PCR 
The summary of the actual PCRs undertaken for the respective gene regions is 
given below in table 6.  
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The primers were diluted to one fifth and one tenth of their initial concentration. 
Thus, when the PCR for a specific region found to be working, it did not work for 
all the samples used for the same reaction. That is why the reaction was repeated 
so many times with same DNA templates and with different samples as well. Not 
many PCRs for the intron regions of the gene were undertaken. The primers for  
intron PCR’s were ordered towards the end of the term. Most of the session was 
consumed to get the exon PCRs working and given more importance.  
 
S.NO. Gene region     
amplified 
No. of PCRs amplified Outcome 
Pass Fail 
1. ALU-TPA 18 6 12 
2. 5’FlankinG 8 2 6 
3. Exon 1- Intron A 8 1 7 
4. Exon 2 - Intron B 
– Exon 3 
29 10 19 
5. Exon 3 32 13 19 
6. Intron C 10 3 7 
7. Exon 4 24 8 16 
8. 3’FlankinG 9 7 2 
Table7: Summary of the PCR reactions undertaken during the session 
The sample A1 was used for all the gradient PCR’s undertaken in the project. The 
Alu TPA PCR conditions were used with a annealing temperature gradient of 
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57±7°C. The numbers on the gel indicate the column number of the gradient PCR 
machine. The columns were at diiferent temperatures. The temperature in the 
gradient PCR machine from 6th column onwards was 57.8°C, 59.1°C, 60.5°C, 
61.6°C, 62°C, 62.5°C and 63.2°C  in the twelth column. Figures 3.3 to 3.9 show 
that the PCR for the three coding sequences of apo A1 gene have worked. The 
gradient PCR was run for the three coding regions to find out the correct annealing 
temperature.  
3.5 Apo A1 5’flanking gradient PCR results 
Expected amplicon size = 330 bp 
The PCR product of the gradient PCR which amplifies 5’flanking is shown in the 
figure 3.3. The standard PCR conditions were used with a annealing temperature 
gradient of 57±7°C. The strongest band could be seen in the 9th well. An extra 
primer band is present in every well at 50 bp. The annealing temperature for this 
region is 60.5°C.  
            
 Figure 3.3: apo A1 5’flanking gradient PCR gel electrophoresis. 6-10 = wells of 
the gradient PCR machine. The numbers on the right of the gel represent the size 
of the bands of the marker in base pairs (bp).  
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3.6 Exon 1/Intron A gradient PCR results 
Expected amplicon size = 348 bp 
The gradient PCR for the exon1/intronA was performed a couple of times but no 
bands were obtained. Therefore, the standard PCR conditions were used to run 
the PCRs for this region of the gene. The outome of the reaction on the gel is 
shown below in fig 3.4.  
             
Figure 3.4: Exon 1/Intron A PCR gel electrophoresis. 6-11 = wells of the gradient 
PCR machine. The numbers on the right of the gel represent the size of the bands 
of the marker in base pairs (bp).  
 
3.7 Exon 2/Intron B/Exon 3 gradient PCR results 
Expected amplicon size = 465 bp 
The PCR product of the gradient PCR, which amplifies Exon 2 – Intron B and 
Exon 3, is shown in the figure 3.5. The control, which does not contain any DNA, 
was run along with all the samples. In 6th well the band is very pale but takes 
shape from the 7th well onwards. The strongest band of approximately 465 bp can 
be seen in the 10th well. So, the temperature in this well can be considered the 
annealing temperature (61.2°C). This temperature was used to run the future 
PCRs for this region.  
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Figure 3.5: Exon2/IntronB/Exon3 gradient PCR gel electrophoresis. 6-10 = wells 
of the gradient PCR machine. The numbers on the right of the gel represent       
the size of the bands of the marker in base pairs (bp). Control = no template DNA 
present. 
 
3.8 Exon 3 gradient PCR results 
Expected amplicon size = 209 bp. 
The PCR product of the gradient PCR, which amplifies Exon 3, is shown in the 
figure 3.6.  
                  
Figure 3.6: Exon 3 gradient PCR gel electrophoresis. 6-12 = wells of the PCR 
radient machine. The numbers on the left and right of the gel represent the size of 
the bands of the marker in base pairs (bp). 
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As mentioned earlier, the sample A1 was used to run the gradient PCR for this 
region. The Alu TPA PCR conditions were used with a annealing temperature 
gradient of 57±7°C. An extra primer-dimer band can be seen on 50 bp in every 
well. The strongest band of approximately 209 bp can be seen in the 11th well. 
This well was the correct annealing temperature (62.5°C) for the Exon 3 region. 
3.9 Intron C gradient PCR results: 
Expected amplicon size = 591 bp 
The PCR product of the gradient PCR,which amplifies Intron C is shown in the 
figure 3.7. The standard PCR conditions were used with a annealing temperature 
gradient of 57±7°C. The strongest and a clear band of approximately desired size 
can be seen in 8th well. In this well was the correct annealing temperature 
(59.7°C). The bands in 9th and 10th well show a tail of bands. This could be due to 
the incorrect volume of the sample or process error. 59.7°C was the temperature 
used to run the future PCR’s for this region. 
                
Figure 3.7 Intron C gradient PCR gel electrophoresis. 6-12 = wells of the PCR 
radient machine. The numbers on the left and right of the gel represent the size of 
the bands of the marker in base pairs (bp). 
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3.10 Exon 4 gradient PCR results 
Expected amplicon size = 674 bp. 
The PCR product of the gradient PCR, which amplifies Exon 4, is shown in figure 
3.8. The sample A1 was used to run the gradient PCR for this region. The Alu TPA 
PCR conditions were used with a annealing temperature gradient of 57±7°C. The 
control, which does not contain any DNA, was run along with all the samples. The 
band in the 6th well is not clear while the strongest band of approximately 674 bp 
can be seen in the 7th well. In this well was the correct annealing temperature 
(58.1°C) for Exon 4 region.  
 
Figure 3.8: Exon 4 gradient PCR gel electrophoresis. 6-10 = wells of the gradient 
PCR machine. The numbers on the right of the gel represent the size of the bands 
of the marker in base pairs (bp). Control = no template DNA present. 
 
 
3.11 3’flanking gradient PCR results 
Expected amplicon size = 364 
The PCR product of the gradient PCR which amplifies Exon 1/ Intron A is shown in 
the figure 3.9. The control, which does not contain any DNA, was run along with all 
the samples. The standard PCR conditions were used with a annealing 
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temperature gradient of 57±7°C. The strongest band of approximately desired size 
could be seen in the 6th well. Therefore, the correct annealing temperature for this 
region was taken to be 57.8°C. All the bands have shown up with an extra primer 
dimer band at 50 bp.  
            
Figure 3.9: 3’flanking region gradient PCR gel electrophoresis. 6-10 = wells of the 
gradient PCR machine. The numbers on the right of the gel represent the size of 
the bands of the marker in base pairs (bp). Control = no template DNA present. 
 
Once the annealing temperature was determined, the polymerase chain reaction 
was performed with different DNA samples. Nine samples were used to run the 
following PCRs. Due to the actual number of PCRs undertaken, some samples 
were totally consumed and could not be used for every PCR. The results of these 
PCRs are presented below 
 
3.12 Apo A1 5’flanking region PCR results 
Expected amplicon size = 330 bp. 
The PCR results for the apo A1 5’flanking region are shown in Fig 3.10. Eight of 
nine samples were run on the gel.  A very clear band can be seen of 
approximately 330 bp in the 5th well (sample A5) and a less intense band for 
samples A1, A3, A4, A7 and A8. Samples A2 and A6 have not produced any 
bands at all.  
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Figure 3.10: apo A1 5’flanking region PCR gel electrophoresis. A1-A8 = subjects   
the numbers on the left of the gel represent the size of the bands of the                     
marker in base pairs (bp). 
 
3.13 Exon1 / Intron A PCR results 
Expected amplicon size = 348 bp. 
The PCR results for exon1 / intron A region are shown in figure 3.11. The control 
was run along with all of the samples. The standard PCR  conditions were used for 
this PCR. So, the annealing temperature for this PCR was 57ºC. Only three 
samples A1, A4 and A9 worked for this PCR and showed bands of approximately 
348 bp.  
                     
Figure 3.11: Exon1/Intron a PCR gel electrophoresis. A1-A9 = subjects. The                    
numbers on the right of the gel represent the size of the bands of the                    
marker in base pairs (bp). Control = no template DNA present. 
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3.14 Exon2 / Exon3/ Intron B PCR results 
Expected amplicon size = 465 bp. 
The PCR results for exon2 / exon3/ intron B are shown in the figure 3.12. The 
annealing temperature for this PCR was 61.2 ºC.                          
                       
 Figure 3.12: Exon1/Exon2/Intron B PCR gel electrophoresis. A1-A5 = subjects. 
The numbers on the right of the gel represent the size of the bands of the marker 
in base pairs (bp). 
 
Five out of nine samples were run on the gel. The marker bands on the left hand 
side have not been clearly captured in the gel picture. Samples A3, A4 and A5 
have given a very strong band of approximately 465 bp.,whereas, samples A1 and 
A2 are comparatively faint. An extra primer-dimer can be seen at 50 bp for all of 
the samples.  
                                         
3.15 Exon 3 PCR results 
Expected amplicon size = 209 bp. 
The PCR results for exon3 region are shown in Fig 3.13. The annealing 
temperature for this PCR was 62.5ºC. Six out of nine samples were run on the gel. 
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The control, which does not contain any DNA, was run on the both ends of the gel 
along with all the other samples. It can be seen that the bands of approximately 
209 bp are apparent in the samples A1, A2, A3 and A5. There is also an extra 
product present at 300 bp. Samples A4 and A6 have not worked at all.                 
                                                  
Figure 3.13: Exon3 region PCR gel electrophoresis. A1-A6= subjects. The 
numbers on the right of the gel represent the size of the bands of the marker in 
base pairs (bp). Control = no template DNA present. 
 
3.16 Intron C PCR results 
Expected amplicon size = 591 bp. 
The PCR results for intron C region are shown in figure 3.14. The annealing 
temperature for this PCR was 59.7ºC. The control, which does not contain any 
DNA, was run along with all the other samples. The strongest band of 
approximately 591 bp can be seen with a trail for sample A9. Samples A1, A3 and 
A8 have given bands with a trail as well. Samples A2, A4, A5, A6 and A8 did not 
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Figure 3.14: Intron C region PCR gel electrophoresis. A1-A9 = subjects. Control = 
no template DNA present. The numbers on the right of the gel represent the size 
of the bands of the marker in base pairs (bp). 
 
 
3.17 Exon 4 PCR results 
Expected amplicon size = 674 bp. 
The PCR results for exon 4 region are represented in the figure 3.15. The 
annealing temperature for this PCR was 58.1ºC. Four out of nine samples were 
run on the gel. The control, which does not contain any DNA, was run along with 
all the other samples. Samples A1, A2 and A3 have given very clear bands of 
approximately 674 bp along with a fainter band at about 500 bp. But the bands 
show a trail all along their way in the gel. Sample A4 shows a very faint band. 
There is an extra primer-dimer band present at 50 bp.   
 
  Apolipoprotein A1 and Polymorphisms                                                                                                                                                                  
 




Figure 3.15: Exon 4 region PCR gel electrophoresis. A1-A4 = subjects. The 
numbers on the left of the gel represent the size of the bands of the marker in 
base pairs (bp). Control = no template DNA present. 
 
3.18 Apo A1- 3’flanking PCR results 
Expected amplicon size = 364 bp. 
The PCR results for the apo A1 3’flanking region are shown in figure 3.16. the 
annealing temperature for this PCR was 57.8ºC The control, which does not 
contain any DNA, was run along with all the other samples. Only samples A1, A3 
and A9 have given the desired band of approximately 364 bp. Addittionaly there is 
a faint band at about 500 bp in samples A1, A3 and A9. The primer-dimer bands at 
50 bp can also be seen and are very faint.  
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Figure 3.16: apo A1 3’flanking region PCR gel electrophoresis. A1-A9 = subjects. 
The numbers on the right of the gel represent the size of the bands of the                  
marker in base pairs (bp). Control = no template DNA present. 
         
A calibration curve relating distance moved to the size of the marker agraph can 
be obtained (figure 3.17) from the marker lanes.  By measuring the distance 
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4.1 Sequencing  
 
60 samples were sent for sequencing. The samples were sequenced with both 
forward and reverse primers. Not all the samples were sequenced successfully 
with the forward and reverse primer for the same sample. Reverse sequences 
were converted to reverse complements to be compatible with the forward 
sequences. The sequences were edited in the Bio-Edit program and exported into 
the Fasta format. The edited sequences were then aligned with the original 
database gene sequence in CLUSTAL W.  Lack of alignment of sequences will 
usually involve miscalling of bases, each sequence should therefore be run five or 
six times on each sample. That was not the case here. Polymorphisms should be 
consistent variants in a sample. There was insufficient time and resources to cover 
all statistical probabilities. The summary of the actual samples sent for sequencing 
for the respective region of the gene are listed below in the table 7. 




1. 5’Flanking 6 5 1 
2. Exon 1- Intron A 2 -- 2 
3. Exon 2 - Intron B – 
Exon 3 
16 5 11 
4. Exon 3 16 3 13 
5. Intron C 2 -- 2 
6. Exon 4 12 3 13 
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7. 3’Flanking 6 -- 6 
                 Table 8: summary of the samples sequenced during the term 
 
Successful sequencing results are represented below according to the different 
regions of apo A1 gene.  
4.2 Apo A1 5’flanking region 
The sequence of the apo A1 5’flanking region is given below. The bold letters 
refers to the nucleotide where the polymorphism or a miss calling of base may be 
present.  
 
  1  tctccctgga atgctggtgg tgggggaggc agtctccttg gtggaggagt cccagcgtcc 
 61 ctcccctccc ctcctctgcc aacacaatgg acaatggcaa ctgcccacac actcccatg      
121 aggggaagg gatgagtgca gggaaccccg accccacccg ggagacctgc aagcctgcag       
181 acactcccct cccgccccca ctgaaccctt gacccctgcc ctgcagcccc cgcagcttgc      
241 tgtttgccca ctctatttgc ccagccccag ggacagagct gatccttgaa ctcttaagtt       
301  ccacattgcc aggaccagtg agcagcaaca 
 
 
The Clustal multiple alignment is shown in figure 4.1 for the samples sequenced 
with the forward primer of apo A1 5’flanking region. There is an insertion of base G 
at position 131 in all the samples, which is not present in the original gene 
sequence. The reference sequence of of apo A1 5’flanking region in the clustal 
alignment can be matched with the original gene sequence of the gene. Because 
of the miscalling bases or sequencing error at positions 131, 149, 150, 162 and 
183, the position of the bases has moved in the alignment. The sample A8 shows 
an apparent insertion of bases A, G, T and T at positions 146, 149, 162 and 184, 
respectively. In sample A7 alignment, the nucleotide C is replaced by T at position 
169 and an insertion of nucleotide T at position 184.  
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4.3 Exon 2/ Intron B/ Exon 3 Region 
 
The gene sequence of Exon 2/ Intron B/ Exon 3 region is given below. 
 
581 catgctgaag 
591 gcaccccact cagccaggcc cttcttctcc tccaggtccc ccacggccct tcaggatgaa 
651 agctgcggtg ctgaccttgg ccgtgctctt cctgacgggt aggtgtcccc taacctaggg       
711 agccaaccat cggggggctt tctccctaaa tccccgtggc ccaccctcct gggcagaggc  
771 agcaggtttc tcactggccc cctctccccc acctccaagc ttggcctttc ggctcagatc     
831 tcagcccaca gctggcctga tctgggtctc ccctcccacc ctcagggagc caggctcggc   
891 atttctggca gcaagatgaa cccccccaga gcccctggga tcgagtgaag gacctggcca  
951 ctgtgtacgt ggatgtgctc aaagacagcg gcagagacta tgtgtcccag tttgaaggct 
1011 ccgccttggg aaaacagcta aagtaaggac ccagcct 
 
The Clustal multiple alignment is shown in figure 4.3 for the samples sequenced 
with the forward primer of exon 2/ intron B / exon 3. The samples A3, A4, and A5 
were sequenced successfully and show no variation from the original gene 
sequence until base number 929. Where as, the sequencing for samples A1 and 
A2 were failed partially.  
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Figure 4.3 Clustal multiple alignment of exon2/intronB/exon3 region (forward 
primer sequencing). 
 
The variations in the sequences in Clustal multiple alignment of 
exon2/intronB/exon3 is shown in the figure 4.4. There is a miscalling of a base at 
position 930 for all the samples including the reference sequence. There is an 
apparent insertion of nucleotide A at position 985 in sample A5. In sample A3 
alignment, the nucleotide G is replaced by T at position 988 and it shows an 
insertion of nucleotides T and C at positions 1028 and 1042, where as there is an 
insertion base G at the same positions in sample A4 and A5. Due to these 
variations in the sequences the base positions have moved and different from the 
original gene sequence.  
 
 
Figure 4.4: Clustal multiple alignment of exon2/intronB/exon3 region (forward 
primer sequencing). 
 
The reverse complement of the gene sequence of Exon 2/ Intron B/ Exon 3 region 
is given below.  
ggctgggtcc ttactttagc tgttttccca aggcggagcc ttcaaactgg gacacatagt 
ctctgccgct gtctttgagc acatccacgt acacagtggc caggtccttc actcgatccc 
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aggggctctg ggggggttca tcttgctgcc agaaatgccg agcctggctc cctgagggtg 
ggaggggaga cccagatcag gccagctgtg ggctgagatc tgagccgaaa ggccaagctt 
ggaggtgggg gagagggggc cagtgagaaa cctgctgcct ctgcccagga gggtgggcca 
cggggattta gggagaaagc cccccgatgg ttggctccct aggttagggg acacctaccc 
gtcaggaaga gcacggccaa ggtcagcacc gcagctttcat cctgaagggc cgtgggggac 
ctggaggaga agaagggcct ggctgagtgg ggtgccttcag cat 
 
 
The Clustal multiple alignment is shown in figure 4.5 for the samples sequenced 
with the reverse primer of exon 2/ intron B / exon 3. A lot of variations could be 
seen in the sample A5. There is an apparent insertion of nucleotides A, G, A, A, T, 
C, A, C, A, G at positions 717, 718, 728, 733, 749, 755, 756, 763, 781 and 782 
respectively.   
 
Figure 4.5 Clustal multiple alignment of exon2/intronB/exon3 region (reverse 
primer sequencing). 
 
4.4 Exon 3 region 
The gene sequence of Exon 3 region is given below.  
871 ctcagggagc caggctcggc 
891 atttctggca gcaagatgaa cccccccaga gcccctggga tcgagtgaag gacctggcca 
951 ctgtgtacgt ggatgtgctc aaagacagcg gcagagacta tgtgtcccag tttgaaggct 
1011 ccgccttggg aaaacagcta aagtaaggac 
The forward primer sequencing of exon 3 failed. The reverse complement of the 
gene sequence of Exon 3 region is given below. 
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cccaggctgg gtccttactt tagctgtttt cccaaggcgg agccttcaaa ctgggacaca 
tagtctctgc cgctgtcttt gagcacatcc acgtacacag tggccaggtc cttcactcga 
tcccaggggc tctggggggg ttcatcttgc tgccagaaat gccgagcctg gctccctgag 
ggtgggaggg gagacccaga 
The clustal multiple alignment is shown in figure 4.6 for the samples sequenced 
with the reverse primer of exon 3. Samples A1 and A2 show insertions of 
nucleotides at various positions throught out the sequence as compared to the 
reference reverse complement sequence of exon 3.  
 




4.5 Exon 4 region 
The gene sequence of Exon 4 region is given below.  
1591 cagccctcaa cccttctgtc  
1611 tcaccctcca gcctaaagct ccttgacaac tgggacagcg tgacctccac cttcagcaag                      
1671 ctgcgcgaac agctcggccc tgtgacccag gagttctggg ataacctgga aaaggagaca 
1731 gagggcctga ggcaggagat gagcaaggat ctggaggagg tgaaggccaa ggtgcagccc 
1791 tacctggacg acttccagaa gaagtggcag gaggagatgg agctctaccg ccagaaggtg 
1851 gagccgctgc gcgcagagct ccaagagggc gcgcgccaga agctgcacga gctgcaagag 
1911 aagctgagcc cactgggcga ggagatgcgc gaccgcgcgc gcgcccatgt ggacgcgctg 
1971 cgcacgcatc tggcccccta cagcgacgag ctgcgccagc gcttggccgc gcgccttgag 
2031 gctctcaagg agaacggcgg cgccagactg gccgagtacc acgccaaggc caccgagcat 
2091 ctgagcacgc tcagcgagaa ggccaagccc gcgctcgagg acctccgcca aggcctgctg 
2151 cccgtgctgg agagcttcaa ggtcagcttc ctgagcgctc tcgaggagta cactaagaag 
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2211 ctcaacaccc agtgaggcgc ccgccgccgc cccccttccc ggtgctcaga ataaacgttt 
 
 The Clustal multiple alignment is shown in figure 4.7 for the samples 
sequenced with the forward primer of exon 4. The samples A1 and A2 show an 
apparent insertion of nucleotide T at positions 1776, 1778, 1789, 1790, 1821, 
1839, 1843, 1857, 1861 and 1878. In sample A1 and A2, the nucleotide A and T 
are missing at positions 1793 and 1832 respectively.   
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5.1 Discussion  
The aim of the project was to devolp PCR based methods for the detection of 
polymorphisms in the human Apo A1 gene of normal individuals. The specific 
objectives included: 
1. Using Bioinformatics tools, to define appropriate regions of the gene for PCR 
amplification. 
2. To optimise exon, intron and control region PCRs to provide amplicons for 
sequencing. 
3. To sequence amplicons in groups to identify potential polymorphisms. 
4. To use data from 3. In the development of AFLP (amplified fragment length 
polymorphism) or ASO (allele specific oligonucleotide) methods for rapid 
detection of polymorphism. 
 
The project arises form an existing PhD project in which damaged (nitrated) proteins 
were identified from the plasma of claudicants (Heptinstall, J. et al, 2006). The 
nitrated proteins found in these patients (who suffer from severe lower limb 
atherosclerosis making walking difficult) and also in the controls did not yield an 
obvious biomarker for the disease. However, one of the proteins was apolipoprotein 
A-1 (Apo A1) which has a well known role in atherosclerosis but which can change if 
the protein changes. 
 
Apo A1 is the major protein of HDL and therby promotes cholesterol efflux from the 
tissue to the liver for extraction; thus its role is anti atherogenic. However there are 
variants of the APO A1 that are either more anti or even pro-atherogenic in relation 
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the the wild type allele. These variants in the coding regions (exons) of the gene are 
quite rare. The best known anti-atherogenic mutation, known as Apo A1 (Milano) 
was found over 20 years age in a few families in Limone on Lake Grada – today 
there are 36 individuals with this allele – where it confers protection against 
atherosclerosis and consequent cardiac disease (Parolini, C. et al, 2005). In the 
main though, variant alleles are pro-atherogenic but not common. Thus screening 
for amino acids substitutions in the Apo A1 of 32,000 new borns in Germany 
revealed 16 variants (1 in 2000) in some of which the Apo A1 (and HDL) 
concentration was decreased (Eckardstein, A. et al, 1989). Also in Germany, 1 in 
750 of a randomly screened population of 2,282 showed a pro-atherogenic 
mutation, Apo A1Marburg (Utermann, G. et al, 1982), whilst only 3 cases of 
mutation leading to Apo A1 deficiency have been described from western Jpan 
(Sasaki, J. et al, 2000). 
 
Mutations in the non coding regions of the gene are more common, but not normally 
associated with Apo A1 deficiency and disease. Thus an Sst-1 RFLP in the 3’ 
flanking region was found in 1 in 20 people in the UK but with no effect on Apo A1 
levels (Rees, A. et al, 1985). 
 
Since there was no biomarker nitrated protein found in claudicants that was not also 
present in controls, it is possible that the claudicants may have a pro-atherogenic 
variant of Apo A1. The proposed project therefore aimed to establish the methods, 
in control subjects, that can be applied to claudicant samples at a later date. It was 
not anticipated that any polymorphisms would be found in the exons; there is a<5% 
probablility of finding a polymorphism in the less significant and flanking regions. 
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Many studies have been undertaken to find mutations in the apo A1 gene. Most of them 
showed variation in the primary structure of the protein resulting from differences in the 
sequence of the gene. All mutations were found in people who already had some 
clinical symptoms. This is why the people without mutations only have lower probability 
of developing the disease. 
 
The gene products from the apolipoprotein (APO) A1/C3/A4/A5 gene cluster 
(11q23–24) are involved in lipid metabolism. Apolipoprotein (apo) A1 comprises 
approximately 70% of the high-density lipoprotein (HDL) particle. It acts as a cofactor of 
lecithin-cholesterol acyltransferase in facilitating the transport of cholesterol from the 
peripheral tissues to the liver in a process known as reverse cholesterol transport. The 
statistical associations between variation in plasma levels of HDL-C, TC and TG and 
single-site and haplotype variations in the apo A1 gene have clearly established the 
influence of this gene in determining phenotypic variability. The present study was 
undertaken to investigate the reproducibility of the apo-A1 gene sequence in normal 
healthy Caucasian control individuals from Coventry University, UK for a better 
assessment of role of apo A1 mutations in conferring risk of artherosclerosis in 
claudicants. Some apparent gene variations were found. It is however difficult to make 
any inference how these variations could be associated with artherosclerosis in 
claudicants. 
 
The main reason for this was the small sample size which was further reduced 
due to failed sequencing reaction in some samples. We did not identify any novel 
mutations in the sample studied and some of these mutations primarily the one in 
intronic region are known to be commonly polymorphic. True estimates cannot be 
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made of the allele and genotype frequencies of the polymorphisms that we observed in 
our small sample size. However our preliminary study provides the basis for further 
investigation of the entire spectrum of mutations in the apo A1 gene. It will be 
interesting to address the following questions in further study. 
 
What is the gamut of rare mutations in apo A1 that could possibly explain some 
high penetrance effects of this gene in predisposition to artherosclerosis in claudicants? 
Are there any population specific disease risk alleles that enhance risk? 
 
The Alu TPA PCR was performed during the first phase of the project. And, the master 
mix from this PCR was also used for the detection of the correct annealing temperature 
of different coding and non-coding regions of apo A1 gene. The PCR conditions used 
for the Alu TPA PCR are the standard PCR conditions to begin with. That is why the 
same conditions were used to detect the annealing temperature of the apo A1 gene 
regions. As mentioned in the results section, additional bands were seen on every gel 
of the gradient PCR.  In gradient PCR the reactions which were not optimised gave the 
non specific DNA products or did not produce any any amplified products at all. Once 
the annealing temperature was detected, the PCRs for all the samples were performed. 
But the desired PCR products were not obtained from all of the DNA samples. At times, 
non specific or no PCR products were obtained. The reasons may be the different 
concentrations or the purity level of the samples. 
 
DNA purification could be another reason of PCR failure. As it has been mentioned in 
earlier sections, the A 260/280nm ratio was not even close to the value of 2 for all the 
subjects. Sample A1 has A260/280nm ratio of 1.89. This sample has given a product 
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band in almost every reaction. Where as other samples sometimes worked in one 
reaction and sometimes not. The A260/230nm ratio was low for each sample. Apart 
from any human errors the value of this purification ratio needs to be considered 
everytime a PCR is done.  
 
After the gradient PCRs, the clear bands from the eight subjects were expected. But, it 
did not happen for each and every sample.  The exon 3 PCR results (figure 3.13) show 
very bright bands of approximately 300bp for samples A1, A2, A3 and A5. But, samples 
A4 and A6 failed to produce any bands at all. The concentration of the DNA templates 
varied from 24.3ng/µl (A4) to 104ng/µl (A1).  
The concentration of sample A5 is 37ng/µl. There is not much difference between the 
concentration of sample A4 and A5 as that of sample A1 (104 ng/µl) and A5. The DNA 
purification level is more for sample A4 (A260/280=1.47) than that of sample A5 (1.31). 
Either a measurement error had occurred for sample A4 or a human error during the 
preparation of PCR. The PCR’s of the non-coding regions of apo A1 gene did not give 
any sound results. 
 
The sequencing reactions were not successful. All the samples could not be sequenced 
for their reverse and forward primers. Some falied for both of the primers and some 
worked for forward and some for reverse primers. This was the major variable in the 
process to draw any inferences of any polymorphisms present in the study of this small 
sample size. The sequences show frequent miscalling of the bases. The insertion of 
various nucleotides could be seen at various places in a sequence in all the samples. 
At most places it was the sequencing error. Intron regions of the gene were not 
sequenced successfully. The miscalling of bases in the sequencing reaction on an 
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average is 5 per 100 bases. There is not enough data to compare the results of introns 
and exons.  
 
Cross contamination could be another reason for PCR to failure. In the beginning of the 
project none of the PCRs seemed to be working. It was later on revealed that there 
could be a chance of contamination of the DNA template. Since then, a negative control 
sample, which does not contain and DNA template, was run along with all the other 
samples. The primers, PCR buffer and other solutions used for the reaction could be 
cross contaminated. Eventually, after making fresh PCR buffer solution and running 
control samples, a lot of improvement was seen in the PCR results. The other reason 
could be the level of DNA purification ratio. The DNA isolation protocol was followed 
with all precautions. An absorbance 260/280 nm ratio of 1.8 could not be achieved for 
any sample. This needs to be amended for the future PCR work. The concentration of 
the primers was changed to achieve good PCR results. The concentration was lowered 
to one fifth and one tenth of their original. Irrespective of the sample concentration, 5µl 
of the DNA template solution was used for every reaction. This was the major variable 
in the procedure. This should be avoided in future PCR work by calculating the amount 
of template DNA. 
 
Multiple repetition of PCR has to be run in order to find any differences in the 
sequences. This should be done with the patients who already have developed clinical 
symptoms of atherosclerosis, because otherwise a mutation is unlikely. It can be said 
that the PCR program did not happen to work with every DNA sample. It is expected 
that the higher the DNA amount is the stronger is the PCR product on the gel. Because, 
more ethium bromide can bind to more available DNA and consequently the resulting 
  Apolipoprotein A1 and Polymorphisms                                                                                                                                                                  
  Sumit Bhagat 
65 
fluorescence is more intensive. But some samples with higher concentration failed to 
produce such kind of bands, which might be due to any human errors or the failure of 
program. Sample A1 (104ng/ml) and A2 (61.6ng/ml) were the high yielding samples. 
They showed the product band in almost every reaction. 
Taq-polymerase is a thermostable polymerase used in the PCR to generate the 
amplicon. One unit of Taq was used in every reaction. One of its drawbacks is the low 
replication fidelity as it lacks a 3’ to 5’ exonuclease proofreading mechanism. The error 
rate of taq polymerase is 1 in 9000 nucleotides. But it seems that either the error rate of 
the taq is quite high in the process or it has to do with the purification of DNA. Taq Man 
real time PCR method could be used to overcome this. It would help to measure the 
accumulation of the product at exponential stages of the reaction. Apparently, the focus 
of the project was not on the expression of apo A1 gene.  
 
Other techniques like quantitative PCR could be used in the future to quantify either the 
starting amounts of DNA template or at the end of the reaction (end point assay). When 




When there is a difference in the DNA sequence in a population, or the occurance of 
two or more genetically determined phenotypes together in such a manner that the 
rarest of them cannot be maintained merely by recurrent mutation, it gives rise to a 
polymorphism. It may be induced by an external agent such as virus or radiation .And if 
the DNA sequence is found to be associated with any disease is called as genetic 
mutation. Any locus with more than one allele is polymorphic. 
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Mutation is change in DNA sequence from normal. Polymorphism if they exist can be 
SNP, insertion, deletion anywhere in the gene. The different types are explained as 
follows: 
 
Single nucleotide polymorphism (SNP) 
It is the most common type of polymorphism. In this type of variation the single base 
differs between individuals. For example, A is replaced by G. it generally occurs in the 
gene and the surrounding area of genome which control their expression. It may not 
have a very large effect but still it influences the activity of the encoded protein 
(Strachan, T and Read, A. 1996). 
 
Restriction fragment length polymorphism (RFLP) 
It is a technique in which organisms may be differentiated by analysis of patterns 
derived from the cleavage of their DNA. If two organisms differ in t he distance between 
the cleavage of a particular restriction endonuclease , the length of the produced 
fragments will differ when DNA  is digested within a restriction enzyme. The pattern can 
be used to segregate species from one another.  
 
Restriction endonucleases are the enzymes which break DNA molecules at a particular 
nucleotide depending on the type of enzyme used. it is basically derived from bacteria. 
The number of produced fragments depends on the length of the sequence. More 
number of fragments is generated with the shorter sequence. And so often the different 
sizes of the fragments are produced if the molecules have different nucleotide. This can 
further be separated by gel electrophoresis.  
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RFLP can be used to detect the diseased gene in the body by the domain of its 
presence or absence. According the concept of Crossing Over RFLP may get linked to 
a mutant gene in some people that’s why all the healthy people are supposed to 
undergo testing as well who are living the subjects. They may be either homozygous or 
heterozygous (Strachan, T and Read, A. 1996). 
 
Generally the mutations are not associated with a disease but rather they are present in 
the noncoding DNA sequences. As a large number of recognition sequences are 
known for type 2 restriction endonucleases , many point mutations polymorphism will 
be characterised by alleles which possess or lack a recognition site for a specific 
restriction endonuclease and therefore display restriction site polymorphism(RSP). 
The two individuals under the same species range might have the same genome but 
they differ in their nucleotides and the restriction sites. So, therefore, two detectable 
alleles with a lacking and possessing specific restriction site are present in the 
restriction site polymorphism. 
Besides following a particular sequence of DNA, RFLP can be used to determine 
source of DNA in criminal or paternity cases and measurement of recombination rates 
which further helps to build the genetic maps of chromosomes. 
 
VARIABLE NUBER OF TANDEM REPEATS (VNTR) 
The sequences of DNA in the chromosomes are repeated a number of times, precisely 
known as tandem repeats. DNA probing is used to detect the VNTR polymorphism 
within the allele samples having different VNTR. For this, DNA is acted upon by 
restriction endonucleases that will find a restriction site with a VNTR locus. The 
fragments produced are segregated by gel electrophoresis and then hybridised to from 
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the respective locus. The different sizes of the restriction sites present the number of 
repeated unit. Usually the repeat lengths are considered in the 5-64bp region which 
differentiate it from the microsatellite DNA or the simple tandem repeat polymorphism. 
If the VNTR locus is from repeated DNA fragments then complex polymorphic pattern is 




LDL cholesterol has been given the prime consideration for a long time. But now for the 
last two decades, the researchers have started giving emphasis on the low levels of 
HDL cholesterol, which is equally important because of the presence APO A1and 
relation to certain cardiovascular diseases. Low HDL is atherosclerotic marker.  ABCA1 
has been found to be involved in the first step of cholesterol efflux, so it has started 
gaining importance in the new researches to give the additional protection towards 
atherosclerosis. The PCR procedure used in the project was successful for the 
amplification of all the exons and introns of apo A1 gene. Nevertheless, further work is 
needed to improve the the amplification procedure. The sample size should be big 
enough to make any conclusions for any polymorphisms present. The sequencing 
results do have many errors which can not be avoided and have to manually edited. 
There are certain details which need to be worked out such as: 
• PCR thermal profile (primer annealing, extension, denaturation, ramp times and 
number of cycles. 
• Magnesium ion concentration 
• Primer design and concentration 
• Template quality and concentration 
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• PCR buffer 
• dNTP concentration 
• Addition of PCR enhancers 
• Avoidance of PCR inhibitors 
• Secondary PCR with nested primers 
• Hot start PCR 
 
The sequencing results showed amplicons of shorter length than expected. The 
sequencing was done directly from the end of each amplicon. Better results can be 
achieved with sequencing starting in the strand and not at the end. These kinds of 
strands can be gained with nested PCR, where the product of the first PCR is used in 
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